Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging

American Journal of Roentgenology

Volumn 173, Issue 1, 1999, Pages 173-178

  Grubnic, S ^a,b   Padhani, A R ^a   Revell, P B ^a   Husband, J E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FERUMOXSIL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; BREATH HOLDING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; FEMALE; HUMAN; IMAGE QUALITY; INTESTINE DISTENSION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033003914     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.173.1.10397122     Document Type: Article

References (17)

1. Young SW, Qing F, Rubin D, et al. Gadolinium zeolite as an oral contrast agent for magnetic resonance imaging. J Magn Reson Imaging 1995;5:499-508
2. Wallengren NO, Holtas S, Andren-Sandbeig A, Bach-Gansmo T. MR imaging of the pancreas at 0.3 T using a super-paramagnetic oral contrast medium. Acta Radiol 1994,35:147-151
3. Scheidler J, Heuck AF, Meier W, Reiser M. MRI of pelvic masses: efficacy of the rectal superparamagnetic contrast agent ferumoxsil. J Magn Reson Imaging 1997;7:1027-1032
4. Hirohashi S, Hirohashi R, Uchida H, et al. MR cholangiopancreatography and MR urography: improved enhancement with a negative oral contrast agent. Radiology 1997;203:281-285
5. Brown JJ. Gastrointestinal contrast agents for MR imaging. Magn Reson Imaging Clin N Am 1996; 4:25-35
6. Kaminsky S, Laniado M, Gogoll M, et al. Gadopentetate dimeglumine as a bowel contrast agent: safety and efficacy. Radiology 1991;178:503-508
7. Laniado M, Kornmesser W, Hamm B, Clauss W, Weinmann HJ, Felix R. MR imaging of the gastrointestinal tract: value of Gd-DTPA. AJR 1988; 150:817-821
8. Listinsky JJ, Bryant RG. Gastrointestinal contrast agents: a diamagnetic approach. Magn Reson Med 1988;8:285-292
9. Li KCP, Tart RP, Fitzsimmons JR, Storm BL, Mao J, Rolfes RJ. Barium sulphate suspension as a negative oral MRI contrast agent: in vitro and human optimization studies. Magn Reson Imaging 1991;9:141-150
10. Mattrey RF, Hajek PC, Gylys-Morin VM, et al. Perfluorochemicals as gastrointestinal contrast agents for MR imaging: preliminary studies in rats and humans. AJR 1987;148:1259-1263
11. Hahn PF, Stark DD, Saini S, Lewis JM, Wittenberg J, Ferrucci JT. Ferrite particles for bowel contrast in MR imaging: design issues and feasibility studies. Radiology 1987;164:37-41
12. Lonnemark M, Hemmingson A, Bach-Gansmo T, et al. Effect of superparamagnetic particles as oral contrast medium at magnetic resonance imaging: a phase I clinical study. Acta Radiol 1989;30:193-196
13. MacVicar D, Jacobsen TF, Guy R, Husband JE. Phase III trial of oral magnetic particles in MRI of abdomen and pelvis. Clin Radiol 1993;47:183-188
14. Rinck PA, Smevik O, Nilsen G, et al. Oral magnetic particles in MR imaging of the abdomen and pelvis. Radiology 1991;178:775-779
15. Hahn PF, Stark DD, Lewis JM, et al. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 1990;175:695-700
16. Saunders DR, Wiggins HS. Conservation of mannitol, lactulose and raffinose by the human colon. Am J Physiol 1981;214:397-402
17. Semelka RC, Chew W, Hricak H, Tomei E, Higgins CB. Fat-saturation MR imaging of the upper abdomen. AJR 1990;155:1111-1116